CMND and SPRC Related Headlines
Go Back- SciSparc unit files U.S. patent for MDMA-PEA combination for PTSD
- SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
- Clearmind Medicine files Hong Kong patent for depression therapy combo
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
- Clearmind Medicine receives international patent for weight loss therapy
- Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
- SciSparc files Israeli patent for depression treatment combination therapy
- SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- Clearmind Medicine files Israeli patent for depression treatment
- Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- SciSparc and Clearmind publish patent application for binge disorders
- SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
- Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders
CMND and SPRC Related Press Releases
Go Back- SciSparc: NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
- Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
- Clearmind Medicine Announces Publication of International Patent for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
- SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
- SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders
- Clearmind Medicine Announces Publication of U.S. Patent Application Targeting Binge Behavior Disorders

